Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 6
2004 9
2005 8
2006 7
2007 11
2008 8
2009 9
2010 16
2011 21
2012 18
2013 17
2014 11
2015 27
2016 29
2017 26
2018 24
2019 26
2020 32
2021 44
2022 36
2023 23
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

374 results

Results by year

Filters applied: . Clear all
Page 1
Availability of genome-matched therapy based on clinical practice.
Hayashi N, Mori S, Ohmoto A, Fukada I, Yamazaki M, Hosonaga M, Wang X, Ueki A, Kiyotani K, Tonooka A, Takeuchi K, Takahashi S. Hayashi N, et al. Among authors: takahashi s. Int J Clin Oncol. 2024 Apr 26. doi: 10.1007/s10147-024-02533-z. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38668785
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Seiwert TY, Wildsmith S, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, Weiss J, Machiels JP, Baxi S, Baker V, Evans B, Morsli N, Jill Walker, Real K, L'Hernault A, Psyrri A. Seiwert TY, et al. Among authors: takahashi s. Cancer Immunol Immunother. 2024 Mar 2;73(4):70. doi: 10.1007/s00262-024-03643-3. Cancer Immunol Immunother. 2024. PMID: 38430375 Free PMC article.
374 results